Stock Monitor: BioMarin Pharma Post Earnings Reporting

LONDON, UK / ACCESSWIRE / April 27, 2018 / Active-Investors.com has just released a free research report on Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) ("Concert"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CNCE as the Company's latest news hit the wire. On April 25, 2018, the Company announced that it has completed patient enrollment of its Phase-2a trial assessing CTP-543 for the treatment of moderate-to-severe alopecia areata, an autoimmune disorder in which the immune system attacks hair follicles, resulting in patchy or complete hair loss. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), which also belongs to the Healthcare sector as the Company Concert Pharma. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=BMRN

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Concert Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=CNCE

Primary Endpoint is Hair Loss at Week 24 as Measured by Severity of Alopecia Tool

The Phase-2a trial is a double-blind, randomized, placebo-controlled, sequential dose trial to evaluate the safety and efficacy of CTP-543 in adult patients with moderate-to-severe alopecia areata. Around 90 patients were randomized to receive one of two doses of CTP-543 (4 mg or 8 mg twice daily) or placebo. The primary outcome measure will utilize the severity of alopecia tool (SALT) after 24 weeks of dosing. The protocol may be amended to explore 12 mg twice daily of CTP-543. Concert is likely to report topline data from the 4 mg and 8 mg cohorts of the Phase-2a trial in Q4 2018. Additionally, a Phase-2b clinical trial is expected to begin in 2019.

FDA Granted Fast Track Designation to CTP-543 for Treatment of Alopecia Areata

On January 12, 2018, the US Food and Drug Administration (FDA) granted Fast Track designation for CTP-543 for the treatment of moderate-to-severe alopecia areata. Fast Track designation is a process designed to facilitate the development and expedite the review of new therapies to treat serious conditions and address unmet medical needs.

About Alopecia Areata

Alopecia areata is peculiar form of hair loss that usually affects the scalp but can occur on any hair-bearing skin. Alopecia areata produces one or more patches of balding without any obvious change in the texture of the affected skin. It is thought to be an autoimmune disorder, in which hair follicles, are damaged by a misguided immune system. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

About CTP-543

CTP-543 is an oral selective inhibitor of certain Janus kinases, known as JAK1 and JAK2, that Concert is developing for the treatment of alopecia areata. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib, which is commercially available under the name Jakafi® in the US for the treatment of myelofibrosis and polycythemia vera. Ruxolitinib has been used in an academic investigator-sponsored clinical trial and has been shown to promote hair growth in individuals with alopecia areata. Preclinical studies demonstrated that CTP-543 retains ruxolitinib's JAK1and JAK2 inhibition profile and showed improved metabolic stability relative to ruxolitinib.

About Concert Pharmaceuticals, Inc.

Founded in 2006 and headquartered in Lexington, Massachusetts, Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to address unmet patient needs.

Stock Performance Snapshot

April 26, 2018 - At Thursday's closing bell, Concert Pharma's stock marginally rose 0.91%, ending the trading session at $18.83.

Volume traded for the day: 138.34 thousand shares.

Stock performance in the previous six-month period ? up 8.16%; and past twelve-month period ? up 17.76%

After yesterday's close, Concert Pharma's market cap was at $441.38 million.

Price to Earnings (P/E) ratio was at 4.66.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 1.2% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors